U.S. Population-Based background incidence rates of medical conditions for use in safety assessment of COVID-19 vaccines
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
The Coronavirus Disease 2019 (COVID-19) pandemic has had a devastating impact on global health, and has resulted in an unprecedented, international collaborative effort to develop vaccines to control the outbreak, protect human lives, and avoid further social and economic disruption. Mass vaccination campaigns are underway in multiple countries and are expected worldwide once more vaccine becomes available. Some early candidate vaccines use novel platforms, such as mRNA encapsulated in lipid nanoparticles, and relatively new platforms, such as replication-deficient viral vectors. While these new vaccine platforms hold promise, limited safety data in humans are available. Serious health outcomes linked to vaccinations are rare, and some outcomes may occur incidentally in the vaccinated population. Knowledge of background incidence rates of these medical conditions is a critical component of vaccine safety monitoring to aid in the assessment of adverse events temporally associated with vaccination and to put these events into context with what would be expected due to chance alone. A list of 22 potential adverse events of special interest (AESI), including neurologic, autoimmune, and cardiovascular disorders, was compiled by subject matter experts at the U.S. Food and Drug Administration and the Centers for Disease Control and Prevention. The most recently available U.S. background rates for these medical conditions, overall and by age, sex, and race/ethnicity (when available), were sourced from reported statistics (data published by medical panels/ associations or federal government reports), and literature reviews in PubMed. This review provides estimates of background incidence rates for medical conditions that may be monitored or studied as AESI during safety surveillance and research for COVID-19 vaccines and other new vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
Virani, S. S., Alonso, A., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Delling, F. N., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000757 · Cited by 9,175
Incidence of early loss of pregnancy
Wilcox, A. J., Weinberg, C. R., O'Connor, J. F., Baird, D. D., Schlatterer, J. P., Canfield, R. E., Armstrong, E. G., & Nisula, B. C. (1988) · New England Journal of Medicine · doi:10.1056/nejm198807283190401 · Cited by 2,354
Gee, J., Marquez, P., Su, J., Calvert, G. M., Liu, R., Myers, T., Nair, N., Martin, S., Clark, T., Markowitz, L., et al. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7008e3 · Cited by 395
Self-citationRisk of anaphylaxis after vaccination in children and adults.
McNeil, M. M., Weintraub, E. S., Duffy, J., Sukumaran, L., Jacobsen, S. J., Klein, N. P., Hambidge, S. J., Lee, G. M., Jackson, L. A., Irving, S. A., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.07.048 · Cited by 381 · cited 1×
“31/million vaccine doses administered during a predefined risk period of 0–2 days [105].”
Self-citationBurden of encephalitis-associated hospitalizations in the United States, 1998-2010
Vora, N. M., Holman, R. C., Mehal, J. M., Steiner, C. A., Blanton, J., & Sejvar, J. (2014) · Neurology · doi:10.1212/wnl.0000000000000086 · Cited by 264 · cited 1×
“9/100,000, of which viral etiologies—herpesvirus in particular—were the predominant cause [40].”
Encephalitis hospitalization rates and inpatient mortality in the United States, 2000-2010
George, B. P., Schneider, E. B., & Venkatesan, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104169 · Cited by 263
Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children
France, E. K., Glanz, J., Xu, S., Hambidge, S., Yamasaki, K., Black, S. B., Marcy, M., Mullooly, J. P., Jackson, L. A., Nordin, J., et al. (2008) · PEDIATRICS · doi:10.1542/peds.2007-1578 · Cited by 165 · cited 1×
“A VSD study of children < 18y found a rate of 1/40,000 doses of MMR vaccine administered to children 12– 23 m, which indicated low attributable risk [112].”
Lambert, P.-H., Ambrosino, D. M., Andersen, S. R., Baric, R. S., Black, S. B., Chen, R. T., Dekker, C. L., Didierlaurent, A. M., Graham, B. S., Martin, S. D., et al. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.05.064 · Cited by 119 · cited 1×
“VMED is a theoretical concern for COVID-19 vaccines based on observations with some Middle East respiratory syndrome (MERS) and SARS-CoV-1 experimental vaccines in certain animal models [115].”
Greene, S. K., Rett, M., Weintraub, E. S., Li, L., Yin, R., Amato, A. A., Ho, D. T., Sheikh, S. I., Fireman, B. H., Daley, M. F., et al. (2012) · American Journal of Epidemiology · doi:10.1093/aje/kws195 · Cited by 91
Cited by
Myocarditis With COVID-19 mRNA Vaccines
Bozkurt, B., Kamat, I., & Hotez, P. J. (2021) · Circulation · doi:10.1161/circulationaha.121.056135 · Cited by 806
Oster, M. E., Shay, D. K., Su, J. R., Gee, J., Creech, C. B., Broder, K. R., Edwards, K., Soslow, J. H., Dendy, J. M., Schlaudecker, E., et al. (2022) · JAMA · doi:10.1001/jama.2021.24110 · Cited by 669
Self-citationMyocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military
Montgomery, J., Ryan, M., Engler, R., Hoffman, D., McClenathan, B., Collins, L., Loran, D., Hrncir, D., Herring, K., Platzer, M., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2021.2833 · Cited by 536
Frontera, J. A., Tamborska, A. A., Doheim, M. F., Garcia‐Azorin, D., Gezegen, H., Guekht, A., Yusof Khan, A. H. K., Santacatterina, M., Sejvar, J., Thakur, K. T., et al. (2022) · Annals of Neurology · doi:10.1002/ana.26339 · Cited by 108
Analysis of Myocarditis Among 252 Million mRNA-1273 Recipients Worldwide
Straus, W., Urdaneta, V., Esposito, D. B., Mansi, J. A., Sanz Rodriguez, C., Burton, P., & Vega, J. M. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciac446 · Cited by 41
Metadata
- Authors
- Gubernot, D., Jazwa, A., Niu, M., Baumblatt, J., Gee, J., Moro, P., Duffy, J., Harrington, T., McNeil, M. M., Broder, K., Su, J., Kamidani, S., Olson, C. K., Panagiotakopoulos, L., Shimabukuro, T., Forshee, R., Anderson, S., & Bennett, S.
- Venue
- Vaccine
- Publisher
- Elsevier BV
- Published
- 2021-06
- Volume
- 39
- Issue
- 28
- Pages
- 3666-3677
- ISSN
- 0264-410X (ISSN-L)
- OpenAlex
- W3160661236
- Cited by
- 74
- References
- 9
- FWCI
- 4.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: U.S. Population-Based background incidence rates of medical conditions for use in safety assessment of COVID-19 vaccines. https://app.cochat.ai/papers/10.1016/j.vaccine.2021.05.016
- The paper
- Gubernot, D., Jazwa, A., Niu, M., Baumblatt, J., Gee, J., Moro, P., Duffy, J., Harrington, T., McNeil, M. M., Broder, K., Su, J., Kamidani, S., Olson, C. K., Panagiotakopoulos, L., Shimabukuro, T., Forshee, R., Anderson, S., & Bennett, S. (2021). U.S. Population-Based background incidence rates of medical conditions for use in safety assessment of COVID-19 vaccines. Vaccine. https://doi.org/10.1016/j.vaccine.2021.05.016
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.